Please login to the form below

Not currently logged in
Email:
Password:

Cancer therapy

This page shows the latest Cancer therapy news and features for those working in and with pharma, biotech and healthcare.

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

cancer with encouraging early clinical data and a potential novel hormonal therapy backbone for HR+ breast cancer,” said Jeff Settleman, chief scientific officer for oncology research and development at Pfizer. ... Looking ahead to 2022, the two

Latest news

More from news
Approximately 1 fully matching, plus 481 partially matching documents found.

Latest Intelligence

  • Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy

    Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... targets of small cell lung

  • China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

    There was no robust, regulatory control but that has changed and any cell therapy now has to be properly approved.”. ... Tightening up regulatory policies was vital in order to move on from the cell therapy lowlight that saw a 21-year-old student die

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    Diefenbach said: “The promise of being able to tailor cancer therapy to biology and risk is at the forefront of the drive to discover novel biomarkers. ... The idea of cancer biomarkers is to find one that exists to the exclusion or near-exclusion of

More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.

Latest appointments

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell

  • Dr Li Zhou joins TxCell as cell engineering VP Dr Li Zhou joins TxCell as cell engineering VP

    transplantation. He joins from ZMKS International Cancer Therapy Biotechnologies, a Chinese immuno-oncology company, where he served as chief scientific officer and director of research and development.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.

  • Kiadis Pharma appoints Vincent Brichard to supervisory board Kiadis Pharma appoints Vincent Brichard to supervisory board

    protect us from infectious diseases – to recognise and kill cancer cells. . ... Atir achieved some extremely compelling clinical data and the phase II study interim analysis in December demonstrated the drug's true potential as an adjunctive

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...